全文获取类型
收费全文 | 821篇 |
免费 | 55篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 32篇 |
妇产科学 | 5篇 |
基础医学 | 82篇 |
口腔科学 | 11篇 |
临床医学 | 59篇 |
内科学 | 192篇 |
皮肤病学 | 10篇 |
神经病学 | 22篇 |
特种医学 | 85篇 |
外科学 | 84篇 |
综合类 | 136篇 |
预防医学 | 73篇 |
眼科学 | 6篇 |
药学 | 37篇 |
肿瘤学 | 40篇 |
出版年
2022年 | 2篇 |
2021年 | 31篇 |
2020年 | 2篇 |
2019年 | 8篇 |
2018年 | 11篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 12篇 |
2014年 | 10篇 |
2013年 | 13篇 |
2012年 | 22篇 |
2011年 | 18篇 |
2010年 | 29篇 |
2009年 | 28篇 |
2008年 | 36篇 |
2007年 | 33篇 |
2006年 | 33篇 |
2005年 | 25篇 |
2004年 | 37篇 |
2003年 | 23篇 |
2002年 | 28篇 |
2001年 | 21篇 |
2000年 | 21篇 |
1999年 | 25篇 |
1998年 | 39篇 |
1997年 | 24篇 |
1996年 | 32篇 |
1995年 | 16篇 |
1994年 | 35篇 |
1993年 | 12篇 |
1992年 | 8篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 21篇 |
1988年 | 20篇 |
1987年 | 22篇 |
1986年 | 23篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 16篇 |
1982年 | 7篇 |
1981年 | 11篇 |
1980年 | 9篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 4篇 |
1974年 | 3篇 |
1972年 | 3篇 |
排序方式: 共有878条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
HERMAN TOURNAYE RONNY JANSSENS PAUL DEVROEY RK VAN STEIRTEGHEM 《International journal of andrology》1994,17(1):1-8
In order to evaluate the effects of pentoxifylline on sperm motility and longevity, a controlled in-vitro study was conducted on normozoospermic donor semen samples using the Cellsoft automated system for sperm motility analysis. After incubation and selection, pentoxifylline was found to improve the recovery of spermatozoa and to increase their velocity. In the subgroup of progressively motile spermatozoa, curvilinear velocity was also enhanced. It is concluded that pentoxifylline has an effect on the vigour, but not on the pattern, of sperm motion. Pentoxifylline did not improve the motility characteristics of senescent spermatozoa in normozoospermic sperm samples. Sperm survival, as shown by supra-vital staining, and motility longevity both decreased with time after pentoxifylline treatment. 相似文献
6.
V. JNSSON H. D. SCHRDER W. TROJABORG T. STAEHELIN JENSEN E. HIPPE M. MRK HANSEN 《Journal of internal medicine》1992,232(2):185-191
A study of 17 patients with autoimmune axonal or demyelinating peripheral neuropathy in combination with M-component is described. The M-component was associated with MGUS (monoclonal gammopathy of undetermined significance) in 12 patients, CLL in one patient, WaldenstrÖm's disease in one patient, and myeloma in three patients. Immunohistological examination with direct and indirect fluorescence showed binding of antibodies to nerve structures of the same class and light chain as seen in the M-component. In five cases of IgM M-component, the demyelinating neuropathy was caused by binding of the IgM M-protein and complement C3b to myelin-associated glycoproteins (MAG). In 12 cases with axonal neuropathy, binding of IgG to the connective tissue of the peri- and endoneurium was found in 50% of cases, IgM in five cases, and IgD in one case. None of the patients had central nervous system (CNS) symptoms. The clinical and therapeutic difficulties are discussed; only two patients with an acute course responded to immunosuppression. A marked co-expression of other autoimmune phenomena is interpreted in the light of cross-reactions between the autoantibody and similar tissue autoantigens. 相似文献
7.
Protection from environmental tobacco smoke in California. The case for a smoke-free workplace. 总被引:4,自引:0,他引:4
OBJECTIVE--To determine the extent of exposure of nonsmoking indoor workers to environmental tobacco smoke (ETS) according to type of work-site smoking policy, work area, workplace size, and demographic characteristics. DESIGN AND PARTICIPANTS--Participants included 7162 adult, nonsmoking, indoor workers who were interviewed as part of the 1990 California Tobacco Survey. Respondents were asked whether anyone had smoked in their work area within the past 2 weeks. RESULTS--An estimated 2.2 million California nonsmokers were exposed to tobacco smoke at indoor work sites in 1990. Nonsmoker exposure to ETS was 9.3% for those working in a smoke-free worksite, 23.2% for those working where there was only a work-area restriction, 46.7% for those working where there was a policy that did not include the work area, and 51.4% for those working where there was no work-site smoking policy. After adjustment for type of work area (eg, office, open area), workplace size, and demographic factors, it was determined that nonsmokers working where there was only a work-area ban were 2.8 times more likely to be exposed to ETS than those working in a smoke-free work site. In workplaces with no policy or a policy not covering the work area, nonsmokers were over eight times more likely to be exposed to ETS than those who worked in a smoke-free work site. Nonsmokers who were 18 to 24 years of age, male, or Hispanic, and those with less than a high school education had more exposure to ETS. CONCLUSION--These results indicate that adequate protection of nonsmokers from ETS exposure requires a smoke-free work site. 相似文献
8.
9.
Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. 总被引:9,自引:1,他引:8
OBJECTIVE: Two forms of recombinant growth hormone that accelerate the healing of skin graft donor sites in severely burned children were evaluated. SUMMARY BACKGROUND DATA: Growth hormone has been shown to reduce wound healing times in burned pediatric patients. Through genetic engineering, several different forms have been synthesized; however, not all are marketed currently. Two forms of growth hormone were used in these studies, Protropin (Genentech, Inc., San Francisco, CA), a commercially available product that possesses a N-terminal methionine residue not found in the second form Nutropin (Genentech, Inc., San Francisco, CA), which, as yet, is not commercially available. Through the use of recombinant human growth hormone, rapid wound healing may reduce the hypermetabolic period, the risk of infection, and accelerate the healing of donor sites used for grafting onto burned areas. The two structurally different forms of growth hormone were tested for their efficacy in healing donor sites in severely burned children. METHODS: Forty-six children, with a > 40% total body surface area and > 20% total body surface area full-thickness burn were entered in a double-blind, randomized study to receive rhGH within 8 days of injury. Twenty received (0.2 mg/kg/day) Nutropin or placebo by subcutaneous or intramuscular injection beginning on the morning of the initial excision. Eighteen patients who failed the entry criteria for receiving Nutropin received Protropin therapeutically (0.2 mg/kg/day). Donor sites were harvested at 0.006 to 0.010 inches in depth and dressed with Scarlet Red impregnated fine mesh gauze (Sherwood Medical, St. Louis, MO). The initial donor site healing time, in days, was reached when the gauze could be removed without any trauma to the healed site. RESULTS: Donor sites in patients receiving Nutropin (n = 20) or Protropin (n = 18) healed at 6.8 +/- 1.5 and 6.0 +/- 1.5 (mean +/- SD) days, respectively, whereas those receiving placebo (n = 26) had a first donor site healing time of 8.5 +/- 2.3 days. Both groups receiving rhGH showed a significant reduction in donor site healing time compared with placebo at p < 0.01. When subgroups were compared, no difference in healing times could be shown with regards to age or time of admission after injury. CONCLUSION: Our results indicate that both forms of rhGH are effective in reducing donor site healing time compared with placebo and suggest that accelerating wound healing is of clinical benefit because the patients' own skin becomes rapidly available for harvest and autografting. With this increase in the rate of wound healing, the total length of hospital stay can be reduced by more than 25%. 相似文献
10.